Table 3.
Clinical assessment scores, skin physiological measurements and patient subjective scores at baseline (day 0), after 2 weeks and after 4 weeks of treatment with a pseudoceramide-containing moisturizer
| Baseline n = 40 | After 2 weeks n = 40 | After 4 weeks n = 40 | p (for changes between week 0 and 4) | |
|---|---|---|---|---|
| Clinical assessment | ||||
| Median Objective SCORAD (IQR) | 29.1 (21.9–33.7) | 25.1 (19.3–29.2) | 22.0 (21.2–27.8) | <0.001 |
| Median Total SCORAD (IQR) | 38.8 (28.6–43.8) | 29.7 (21.4–38.8) | 28.1 (21.5–35.2) | <0.001 |
| Median TIS score (IQR) | 3 (3–5) | 2 (1–3) | 2 (1–3) | <0.001 |
| Epidermal barrier function tests | ||||
| Median skin hydration, arbitrary unitsa (IQR) | 39.7 (35.3–46.4) | 45.2 (36.4–56.2) | 49.2 (41.2–54.6) | <0.001 |
| Median TEWL, g/m2/h (IQR) | 9.4 (8.1–13.6) | 10.6 (8.5–14.8) | 11.2 (8.8–15.4) | 0.1 |
| Patient subjective symptoms | ||||
| Median DLQI (IQR) | 6.5 (3–11) | 3 (2–7) | 3 (2–7) | <0.05 |
| Median POEM (IQR) | 13 (7–19) | 8 (4–12) | 6.5 (3–10) | <0.001 |
| Median pruritus (IQR) | 6 (5–7) | 4 (2–6) | 4 (2–6) | <0.001 |
| Median insomnia (IQR) | 2 (0–6) | 1 (0–5) | 0 (0–3) | 0.033 |
IQR interquartile range, TIS three-item severity, TEWL transepidermal water loss, DLQI Dermatology Life Quality Index, POEM patient-oriented eczema measure
a Data available only for 34 patients